Abstract WP1: Intravenous Cangrelor as a Rescue Platelet Inhibitor for Emergent Stenting in Ischemic and Hemorrhagic Stroke

Background: Platelet inhibitor loading is commonly used in emergent settings for neurondovascular interventions in which permanent device implantation (eg, a stent or a flow-diverter) is planned. Oral/enteral load of antiplatelets may delay time-sensitive intervention in emergency settings, and intravenous glycoprotein inhibitors have a long half-life making them difficult to reverse should the treatment strategy change or complications (eg, bleeding) occur. Objective: To investigate the safety and utility of Cangrelor, an intravenous P2Y12 receptor inhibitor with immediate onset (within 2 min) and rapid offset (elimination half-life of 3-6 min) of antiplatelet activity for acute stenting in patients with ischemic and hemorrhagic stroke. Methods/Patients: A total of seven patients (at the time of this submission) received intravenous Cangrelor intraprocedurally. Of those, three patients had tandem cervical/intracranial occlusions, necessitating carotid stenting; two underwent intracranial stenting for thr...